The hepcidin-ferroportin axis underlies the pathophysiology of many iron-associated disorders and is a key target for the development of therapeutics for treating iron-associated disorders. The aims of this study were to investigate the dynamics of hepcidin-mediated ferroportin internalization and the consequences of a novel disease-causing mutation on ferroportin function. Specific reagents for ferroportin are limited; we developed and characterized antibodies against the largest extracellular loop of ferroportin and developed a novel cell-based assay for studying hepcidinferroportin function. We show that hepcidin-mediated ferroportin internalization is a rapid process and could be induced using low concentrations of hepcidin. Targeted next-generation sequencing utilizing an iron metabolism gene panel developed in our group identified a novel ferroportin p. D84E variant in a patient with iron overload. Wild-type and mutant ferroportin constructs were generated, transfected into HEK293 cells and analysed using an all-in-one flow-cytometry-based assay to study the effects on hepcidin-mediated internalization and iron transport. Consistent with the classical phenotype of ferroportin disease, the p.D84E mutation results in an inability to transport iron and hepcidin insensitivity. These results validate a recently proposed 3D-structural model of ferroportin and highlight the significance of this variant in the structure and function of ferroportin. Our novel ferroportin antibody and assay will be valuable tools for investigating the regulation of hepcidin/ferroportin function and the development of novel approaches for the therapeutic modulation of iron homeostasis.
of ferroportin mutations is important for clinical treatment and monitoring; current characterization assays require subjective interpretation which can lead to incorrect assignment of sub-types. 7 The recent crystal structure of a bacterial ferroportin homologue, and predicted structure of human ferroportin, has given insights into the regions of the protein and key residues involved in the mechanics of iron transport and the role of hepcidin in modulating function. 8 This information combined with the functional consequences of mutations on the iron transport activity and hepcidin-sensitivity of ferroportin will
give us a greater understanding of the relationships between structure and function and assist in developing new avenues for modulating the hepcidin-ferroportin axis.
We studied the dynamics of ferroportin trafficking, its response to hepcidin and ability to transport iron using a novel antibody recognizing cell-surface ferroportin, and a cell-based assay. Functional characterization of a new mutation in SLC40A1 in a patient with iron overload allowed us to classify the novel variant as iron transport-defective and hepcidin-insensitive, leading to the classical phenotype of ferroportin disease (HH type 4A). 
| M E T H O D S 2.1 | Patient consent

| Patient
A female patient presented in 2000 at 26 years of age with an elevated serum ferritin of 1500 mg/L. Liver biopsy showed normal hepatic architecture but with increased hemosiderin (grade 2 to 4) mainly in the pericanalicular region of zone 1 hepatocytes, with diffuse staining also present in Kupffer cells (Online Supporting Information Figure S1A ,B).
The hepatic iron concentration (HIC) was 250 mmol/g dry weight (normal range: 5-40) and hepatic iron index (HIC/age in years) was 9.6
(normal: <2.0). The serum ferritin and venesection history were recorded over time (Online Supporting Information Figure S1C ). During this period, transferrin saturation was relatively normal, ranging from 17% to 47%. The patient has a family history of iron overload suggestive of autosomal dominant inheritance: father, uncle and a cousin reported as having high serum ferritin levels.
| DNA sequencing
Genomic DNA was amplified using a targeted Ampliseq iron metabolism gene panel (Thermo Fisher Scientific, Waltham, MA), the resultant amplicons sequenced using an Ion Torrent PGM (Thermo Fisher Scientific), and variants annotated by wANNOVAR as previously described. 9 The presence of a novel SLC40A1 variant was validated by PCR amplification of exon 3 and Sanger sequencing as previously described. 10 
| Generation of mutant ferroportin constructs
Wild-type (WT) and p.V162del mutant ferroportin were originally cloned by amplifying cDNA from a lymphoblastoid cell line derived from a patient with p.V162del ferroportin disease, 10 using primers IREG1-F-Nterm and IREG1-R-Nterm. 11 The cDNAs were cloned into the pDHA (neo) plasmid to produce WT (pDHA-Fpn-WT) and p.V162del mutant (pDHA-FpnV162del) ferroportin containing an amino (N)-terminal double-HA tag.
Mutant p.C326Y and p.D84E ferroportin constructs were generated by site-directed mutagenesis using pDHA-Fpn-WT and the primers listed in
Online Supporting Information Table S1 as previously described, except using KOD polymerase (Merck Millipore, Darmstadt, Germany). 11 The presence of the desired mutations was confirmed by DNA sequence analysis.
| Cell lines
The human embryonic kidney cell line (HEK293) was grown in 
| Generation of cell surface-specific ferroportin antibody
The loop between transmembrane (TM) helices 9 and 10 of human ferroportin, 11 comprising amino acids 393 to 450 was amplified from human ferroportin cDNA using the hFpn-loopTM9-10-BamHI-F and hFpn-loopTM9-10-HindIII-R primers (Online Supporting Information Table S1 ) and KOD polymerase (Merck Millipore). The resultant amplicon was digested with BamHI and HindIII and cloned into the pQE30 plasmid (Qiagen, Hilden, Germany) to generate the plasmid pQE30-hFpn-loopTM9-10. pQE30-hFpn-loopTM9-10 was transformed into M15 pRep4 cells (Qiagen) and the expression of His-tagged hFpnloopTM9-10 fusion protein induced by the addition of IPTG. The recombinant protein was purified from lysed bacterial cultures using nickel affinity chromatography as described. 13 Recombinant His-hFpnloopTM9-10 was used to generate antibodies in rabbits and the antibodies purified by affinity chromatography, essentially as described.
14 These were described as Floopn antibodies. 
| Immunofluorescence
| Flow cytometry
| Statistical analysis
Variables were compared between groups using 1-way-analysis of variance (ANOVA) with Tukey's multiple comparison test using the GraphPad Prism 6 software (GraphPad Software, San Diego CA). Graphs were prepared using GraphPad Prism 6 and values are presented as the mean, error bars represent the standard error of the mean (SEM).
| R E S U L T S 3.1 | A novel antibody detects cell-surface expressed ferroportin
We and others have previously shown that both the N-and carboxyl (C)-termini of ferroportin are oriented toward the cytoplasm. 11, 15, 16 Therefore, N-or C-terminal epitope-tagged ferroportin proteins are not amenable to external labelling using epitope-specific antibodies, making it difficult to study hepcidin-induced internalization. We generated rabbit antibodies to the extra-cytoplasmic loop between predicted TM helices 9 and 10 of human ferroportin; these antibodies are referred to henceforth as "Floopn." This 58 amino acid loop, comprising amino acids methionine 393 to valine 450, is the largest extra-cellular loop in the ferroportin protein. which has a minor allele frequency of 0.0074 in Europeans (ExAC).
Heterozygosity for the BMP6:p.L96P variant has been reportedly associated with hyperferritinemia by two groups, 17, 18 however, this is controversial and population genetic analysis of this variant suggests that it is probably at too high a frequency (1 in 67 of the European population are heterozygous) to be a primary cause of iron overload. 19 The novel p.D84E variant in SLC40A1 was considered a more likely candidate for causing the patient's iron overload and was followed up further with functional studies utilizing the Floopn antibody.
| The SLC40A1 p.D84E variant results in iron-transport defective ferroportin
Site-directed mutagenesis was used to introduce the p. Variables were compared between groups by 1-way-ANOVA and Tukey's multiple comparison test (n 5 2 for all groups). Statistically significant differences compared to 0 h and 0 nM hepcidin are denoted as ** P < .01, *** P < .001, and **** P < .0001 [Color figure can be viewed at wileyonlinelibrary.com] As such, the p.D84E variant can also be classified as hepcidin insensitive. In addition to hepcidin sensitivity, this assay was also able to confirm that the p.D84E variant causes a defect in the iron transport ability 
| DISCUSSION
The ability of WT or mutant ferroportin to respond to hepcidin has been studied by many groups, and in the majority of studies has relied on assays that assess the localisation of ferroportin protein by nonquantitative or semi-quantitative methods, such as immunofluorescence analysis 1, 21 and isolation of plasma membrane proteins followed by Western blotting. 22 The cytoplasmic localisation of the N-and Ctermini of ferroportin 8 means that epitope tags inserted at either end of the protein cannot be accessed in non-permeabilized cells. Although some studies have suggested that the C-terminus of ferroportin is located extracellularly, [23] [24] [25] [26] [27] other studies, 11, 15, 16 as well as the current models of human ferroportin structure 11, 28 there has been only one ferroportin antibody that has been reported to bind to the extracellular surface of ferroportin, which has been used by immunofluorescence analysis in studies to determine the molecular mechanisms involved in hepcidin-mediated ferroportin internalization. 12 We have generated a novel antibody directed against the largest extracellular loop of ferroportin; we show that it is highly specific and detects cell surface-exposed ferroportin by immunofluorescence and flow cytometry analysis. Using the Floopn antibody we could measure the hepcidin-mediated reduction in cell surface ferroportin with high sensitivity, using short incubation times and low concentrations of hepcidin, equivalent to reference ranges observed in human serum. 30 The largest decrease in cell surface ferroportin was seen in the first 30 minutes following hepcidin treatment, with a more gradual decline after this point. In contrast the reduction in total ferroportin was slower.
These results indicate that hepcidin has a rapid physiological effect, being able to reduce iron export quickly by removing ferroportin from the cell surface. This is then followed by a more gradual decline in surface localisation and degradation of the protein. We also coupled the also insensitive to hepcidin. This phenomena has also been observed for other iron transport-defective mutants and it has been suggested that the iron transport activity of ferroportin must be intact for it to appropriately respond to hepcidin. 26 While the identified novel p.D84E mutation would appear to be a conservative change, both being small negatively charged amino acids, the majority of functional prediction algorithms predict the change to be deleterious. Further inspection revealed that an aspartic acid at this position of ferroportin is conserved across all species examined, including the bacteria B. Bacteriovorus. 8 The recent crystal structure of the B.
bacteriovorus ferroportin homologue has also revealed a critical role for this residue in its function. Amino acid D69, the bacterial equivalent of human D84, is located at the intracellular end of TM2 and forms hydrogen bonds with the main chain nitrogen atoms of TM11. 8 This interaction forms part of the intracellular gate on the cytoplasmic side of the membrane that holds together the N-terminal and C-terminal lobes of ferroportin in its outward facing state. 8 It is, therefore, highly likely that disruption to D84, similar to other residues that form the intracellular gate, would result in destabilisation of the inter-lobe interface and reduced iron transport activity. 8 Of the seven amino acids that make up the intracellular gate, mutations affecting four have been previously reported in patients with the classical phenotype of ferroportin disease (HH Type 4A). 8 The p.D84E mutation is now the fifth reported to affect the residues that make up the intracellular gate, supporting the recent structural model of ferroportin and highlighting the importance of a correctly functioning intracellular gate for allowing iron to enter the central cavity of ferroportin and eventually traverse the cell membrane. 8 In conclusion, we have followed the dynamics of hepcidinmediated ferroportin internalization using a novel ferroportin antibody and quantitative flow cytometry-based assay. We have shown that internalization is a rapid process and can be detected at low concentrations of hepcidin. Using an all-in-one functional assay we also showed that the novel p.D84E mutation, associated with the classical form of ferroportin disease, is both iron transport defective and hepcidin insensitive. This new antibody and cell-based assay will be valuable in studying the effects of ferroportin variants, in deciphering the mechanisms involved in regulating ferroportin trafficking and cell surface localisation and in the development of potential therapeutic modulators of hepcidin and ferroportin function.
